ACT-709478
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530984

CAS#: 1838651-58-3

Description: ACT-709478 is a Potent, Selective, o rally available triple T-type Ca2+ channel blocker, and is a Drug Candidate for the Treatment of Generalized Epilepsies.


Chemical Structure

img
ACT-709478
CAS# 1838651-58-3

Theoretical Analysis

MedKoo Cat#: 530984
Name: ACT-709478
CAS#: 1838651-58-3
Chemical Formula: C22H18F3N5O
Exact Mass: 425.15
Molecular Weight: 425.415
Elemental Analysis: C, 62.11; H, 4.27; F, 13.40; N, 16.46; O, 3.76

Price and Availability

Size Price Availability Quantity
200mg USD 2450 2 Weeks
500mg USD 3450 2 Weeks
1g USD 4650 2 Weeks
2g USD 7850 2 Weeks
Bulk inquiry

Synonym: ACT-709478; ACT709478; ACT 709478; apinocaltamide

IUPAC/Chemical Name: N-(1-((5-Cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)-phenyl)acetamide

InChi Key: LSYANGLAZUZYFX-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H18F3N5O/c23-22(24,25)21(8-9-21)17-4-1-15(2-5-17)11-20(31)28-19-7-10-30(29-19)14-18-6-3-16(12-26)13-27-18/h1-7,10,13H,8-9,11,14H2,(H,28,29,31)

SMILES Code: O=C(NC1=NN(CC2=NC=C(C#N)C=C2)C=C1)CC3=CC=C(C4(C(F)(F)F)CC4)C=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: ACT-709478 is a potent, selective, orally active, and brain penetrating T-type calcium channel blocker.
In vitro activity: TBD
In vivo activity: In WAG/Rij rats, 10 mg/kg po of 66b (ACT-709478), 66d, or 66e significantly decreased the cumulative duration of absence-like seizures over the next 12 h period by 93, 35, and 79%, respectively, compared to a matched vehicle group (p < 0.001 for 66b and 66e and p < 0.01 for 66d, paired t test, Figure 5a,c,e). Compounds 66b and 66e completely suppressed the absence-type seizures over the first 6 h following administration (Figure 5a,e). Reference: J Med Chem. 2017 Dec 14;60(23):9769-9789. https://pubmed.ncbi.nlm.nih.gov/29116786/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 125.0 293.83

Preparing Stock Solutions

The following data is based on the product molecular weight 425.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Bezençon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, Corminboeuf O, Roch C, Kessler M, Ertel EA, Reymond I, Pfeifer T, de Kanter R, Toeroek-Schafroth M, Moccia LG, Mawet J, Moon R, Rey M, Capeleto B, Fournier E. Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. J Med Chem. 2017 Dec 14;60(23):9769-9789. doi: 10.1021/acs.jmedchem.7b01236. Epub 2017 Nov 20. PMID: 29116786.
In vitro protocol: TBD
In vivo protocol: 1. Bezençon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, Corminboeuf O, Roch C, Kessler M, Ertel EA, Reymond I, Pfeifer T, de Kanter R, Toeroek-Schafroth M, Moccia LG, Mawet J, Moon R, Rey M, Capeleto B, Fournier E. Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. J Med Chem. 2017 Dec 14;60(23):9769-9789. doi: 10.1021/acs.jmedchem.7b01236. Epub 2017 Nov 20. PMID: 29116786.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Richard M, Kaufmann P, Kornberger R, Dingemanse J. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker. Epilepsia. 2019 May;60(5):968-978. doi: 10.1111/epi.14732. Epub 2019 Apr 20. PMID: 31004346.


2: Richard M, Kaufmann P, Ort M, Kornberger R, Dingemanse J. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug. CNS Drugs. 2020 Mar;34(3):311-323. doi: 10.1007/s40263-019-00697-1. PMID: 31994022.


3: Nam G. T-type calcium channel blockers: a patent review (2012-2018). Expert Opin Ther Pat. 2018 Dec;28(12):883-901. doi: 10.1080/13543776.2018.1541982. Epub 2018 Nov 11. PMID: 30372652.


4: Bezençon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, Corminboeuf O, Roch C, Kessler M, Ertel EA, Reymond I, Pfeifer T, de Kanter R, Toeroek- Schafroth M, Moccia LG, Mawet J, Moon R, Rey M, Capeleto B, Fournier E. Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. J Med Chem. 2017 Dec 14;60(23):9769-9789. doi: 10.1021/acs.jmedchem.7b01236. Epub 2017 Nov 20. PMID: 29116786.